美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

TransAtlantic Petroleum Ltd

0.2460

0.0000

成交量：- -

成交額：- -

市值：1,869.66萬

市盈率：-0.46

高：0.2460

開：0.2460

低：0.2460

收：0.2460

52周最高：0.8400

52周最低：0.1200

股本：7,600.26萬

流通股本：3,946.96萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.5370

每股收益(LYR):-0.0973

淨資產收益率：-90.35%

總資產收益率：-7.65%

市淨率：-0.96

市盈率(LYR):-2.53

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

破傷風抗毒素「隱形冠軍」江西生物再衝港股：頻繁股權代持遭遇證監會問詢，營收高度依賴單一產品

江西生物IPO：單一產品依賴症明顯「第二曲線」遙遙無期歷史沿革疑雲密佈遞表前大額派息

江西生物IPO：新一代TAT與資本動作共振，抗血清龍頭的價值突圍之路

新股消息 | 江西生物再次遞表港交所公司為中國及全球最大的人用TAT提供商

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TAT"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"TAT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TAT\",,,,,undefined,":{"symbol":"TAT","market":"US","secType":"STK","nameCN":"TransAtlantic Petroleum Ltd","latestPrice":0.246,"timestamp":1654891200000,"preClose":0.246,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":39469571,"shares":76002557,"eps":-0.53704,"marketStatus":"盤前交易","change":0,"latestTime":"02-10 04:56:25 EST","open":0.246,"high":0.246,"low":0.246,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.53704,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1770733800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1260248400000,"exchange":"AMEX","adjPreClose":0.246,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TAT\",,,,,undefined,":{"symbol":"TAT","floatShares":39469571,"roa":"-7.65%","roe":"-90.35%","lyrEps":-0.097326,"shares":76002557,"dividePrice":0,"high":0.246,"amplitude":0,"preClose":0.246,"low":0.246,"week52Low":0.12,"pbRate":"-0.96","week52High":0.84,"institutionHeld":0.084,"latestPrice":0.246,"eps":-0.53704,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.53704,"open":0.246,"prevYearClose":0.4883},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TAT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-12-18","symbol":"TAT","reason":null,"defaultRemindTime":1608301800000,"announcedDate":"2020-12-15","type":"delisting","dateTimestamp":1608267600000},{"date":"2020-08-12","symbol":"TAT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1597262400000,"name":null,"time":"盤後","dateTimestamp":1597204800000,"actualEps":null},{"date":"2020-06-17","symbol":"TAT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1592424000000,"name":null,"time":"盤後","dateTimestamp":1592366400000,"actualEps":null},{"date":"2020-03-25","symbol":"TAT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1585166400000,"name":null,"time":"盤後","dateTimestamp":1585108800000,"actualEps":null},{"date":"2019-11-12","symbol":"TAT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1573592400000,"name":null,"time":"盤後","dateTimestamp":1573534800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TAT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TAT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TAT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TAT","date":"2020-12-16","current":-0.458066,"percent":0.659761,"low":-69.640654,"twenty":-4.364988,"median":-1.901598,"eighty":-0.296655,"high":9.945011,"avg":-4.27987,"sd":12.072841,"marketCap":19540257},"quantilePoints":[],"updateTime":1770704939382},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TAT\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586872449","title":"破傷風抗毒素「隱形冠軍」江西生物再衝港股：頻繁股權代持遭遇證監會問詢，營收高度依賴單一產品","url":"https://stock-news.laohu8.com/highlight/detail?id=2586872449","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586872449?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 13:36","pubTimestamp":1764049016,"startTime":"0","endTime":"0","summary":"作为国内破伤风抗毒素领域的“隐形冠军”，江西生物超90%收入来自人用破伤风抗毒素，引发业内关注。频繁股权代持遭遇证监会问询招股书显示，目前掌舵江西生物的是一位“90后”。现年32岁的敬玥2017年5月加入江西生物，2022年1月起担任董事长。除了历史股权代持情况遭遇证监会问询，值得注意的是，股权高度集中的江西生物在上市前出现“清仓式分红”。不过，该公司也被指过度依赖单一产品。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1764048924064767127","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["TAT"],"gpt_icon":0},{"id":"2583526419","title":"江西生物IPO：單一產品依賴症明顯「第二曲線」遙遙無期 歷史沿革疑雲密佈遞表前大額派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2583526419","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583526419?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 13:39","pubTimestamp":1763098740,"startTime":"0","endTime":"0","summary":"　　近日，人用破伤风抗毒素提供商江西生物制品研究所股份有限公司向港交所递交IPO申请，拟于港交所主板挂牌上市。　　招股书显示，凭借人用破伤风抗毒素，公司业绩近年实现快速增长，2022年至2024年总收入从1.42亿元增长至2.21亿元，复合年增长率达24.7%；同期利润从2646.8万元提升至7514万元，复合年增长率高达68.5%。然而，在亮眼的业绩表现背后，过度依赖单一产品、错综复杂的股权关系等问题，为其上市之路增添了诸多不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-11-14/doc-infxkapa3028873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TAT"],"gpt_icon":0},{"id":"2582245383","title":"江西生物IPO：新一代TAT與資本動作共振，抗血清龍頭的價值突圍之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2582245383","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582245383?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 17:44","pubTimestamp":1762940695,"startTime":"0","endTime":"0","summary":"近日，江西生物推出新一代破伤风抗毒素（TAT），凭借三大独有技术突破，成功重塑破伤风抗毒素领域的行业标准。","market":"hk","thumbnail":"https://img7.gelonghui.com/column/9.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/9.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3183913","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["TAT"],"gpt_icon":0},{"id":"2578637155","title":"新股消息 | 江西生物再次遞表港交所 公司為中國及全球最大的人用TAT提供商","url":"https://stock-news.laohu8.com/highlight/detail?id=2578637155","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578637155?lang=zh_tw&edition=fundamental","pubTime":"2025-10-26 20:45","pubTimestamp":1761482738,"startTime":"0","endTime":"0","summary":"据招股书披露，江西生物是中国最大的人用破伤风抗毒素提供商和出口商，也是全产业链贯通的抗血清平台商。资料显示，江西生物已建立人用药和兽药的协同产品组合。根据弗若斯特沙利文的资料，江西生物是中国及全球最大的人用TAT提供商，按2024年销量计，市场份额分别为65.8%及36.6%。根据弗若斯特沙利文的资料，公司于中国人用TAT市场一直占据主导地位，市场份额连续18年保持50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","TAT"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TAT\",params:#limit:6,delay:false,,,undefined,":[]}}